Navigation Links
New Data from Silence's Atu027 Anticancer Trial Published at ASCO
Date:5/16/2012

LONDON, May 17, 2012 /PRNewswire/ --

- Atu027, a First in Class RNAi Therapy, Demonstrates Potential

- Antitumour Activity in Cancer Patients and Possible Biomarker Identified

Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces that top line data from its ongoing Phase I trial of Atu027 show that of the 33 patients treated in the first 10 cohorts of the study, 10 patients experienced stable disease after three months. Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. Importantly, among various biomarkers tested, sVEGFR-1 plasma levels decreased significantly upon treatment further confirming a potential biological effect of Atu027.  

Silence will publish the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, at the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois, 1-5 June 2012. Further data from the ongoing Phase I Atu027 clinical study will also be the subject of a presentation with the following details:

Abstract Title: Anti-metastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumours. Abstract #: 98347 Presentation Date/Time: Mon, June 04, 2012 / 16:00 - 18:00 Location: Networking Lounge, Level 3, North Presenters: Klaus Giese [http://silence-therapeutics.com/about-us/man
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
3. Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
4. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
5. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
8. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
9. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
10. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
11. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. (NASDAQ: ... extraordinary general meeting of shareholders in connection with its proposed ... at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 ... Among other agenda items at the extraordinary general meeting, Mylan ... 2:107a of the Dutch Civil Code, of the acquisition of ...
(Date:7/27/2015)... 27, 2015  The fairness of the proposed acquisition ... Jude Medical ("St. Jude") is the subject of an ... rights law firm.  The investigation is focusing on possible ... by the Board of Directors of THOR for agreeing ... 2015, the Company announced it had reached a definitive ...
(Date:7/27/2015)... 27, 2015  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Monday, August ... will lead the call.  Date:Monday, ... 507-2598Pass Code: 68380312 Webcast, including Replay and ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... ... 2015 , ... There has been much discussion in Washington, D.C. ... often overlooked is the over 740,000 miles of municipal sewer lines designed ... facilities. According to the American Society of Civil Engineers , the average age ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step ... Center located at Gary Avenue and Lies Road in Carol Stream. All are welcome. ... awareness, and provide education and help to support individuals and families affected by a brain ...
(Date:7/28/2015)... AURORA, Colo. (PRWEB) , ... July 28, 2015 ... ... education provider to offer online RN to BSN cohorts for Geisinger ... The education partnership provides GHS diploma and associate degree prepared nurses with access ...
(Date:7/28/2015)... ... , ... Scientel is thrilled to announce that they been accepted ... McHenry Convention Center in San Jose, Ca. Scientel will be participating as a Silver ... and the industry’s first polymorphic database will address the critical need of efficiently storing ...
Breaking Medicine News(10 mins):Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3
... and Amortization Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, ... "the Group"), one of the leading Mexican,distributors of pharmaceutical products, ... other products,announces its consolidated financial and operating results for the ...
... WASHINGTON, Feb. 26 The following is a,statement ... Tobacco-Free,Kids:, All Nebraska workplaces, including restaurants, bars ... 2009, thanks to,legislation overwhelmingly approved by the Legislature ... Dave Heineman. Governor Heineman and the,Legislature have delivered ...
... Schnitzer West announced today,that one of the country,s most ... in The Shops at The Bravern in downtown Bellevue ... meet the needs of approximately 2,300,Microsoft employees who will ... beginning this fall., DavidBartonGym will offer Barton,s world ...
... Over 200,of MemorialCare,s top leaders will participate in a ... for Humanity of Orange County. The,home will be renovated ... palsy and is confined to a wheelchair. Halls will ... be given a "makeover" with,upgrades throughout., (Photo: ...
... designed to enhance patient acceptance and ... ... a prescription,laxative product that treats acute and chronic constipation, may be ... MiraLAX(R) and generic PEG 3350 products. Marketed in the,U.S. by Cumberland ...
... for His Support of a New ... Playground, LAS ... social service agency, during a ceremonial session of,the Las Vegas City Council meeting. ... playground fundraising,efforts., Mayor Goodman was presented with a plaque of appreciation by ...
Cached Medicine News:Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:Nebraska's New Smoke-Free Law is Historic Win for Health 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3Health News:MemorialCare Sponsors Habitat for Humanity Santa Ana Home 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: